SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): June 14, 2008
SUNESIS PHARMACEUTICALS, INC. |
| (Exact name of registrant as specified in its charter) |
| | | | | |
Delaware | | 000-51531 | | 94-3295878 |
| (State or other jurisdiction | | (Commission File Number) | | (IRS Employer Identification No.) |
| of incorporation) | | | | |
| | | |
| | | |
341 Oyster Point Boulevard South San Francisco, California | | 94080 |
| (Address of principal executive offices) | | (Zip Code) |
| |
Registrant’s telephone number, including area code: (650) 266-3500 |
| |
Not Applicable |
| (Former name or former address, if changed since last report.) |
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
On June 14, 2008, James A. Wells, Ph.D. notified the Board of Directors of Sunesis Pharmaceuticals, Inc. of his resignation as a director, effective June 25, 2008. Dr. Wells’ resignation was due to personal reasons and not the result of any disagreement with Sunesis on any matter relating to its operations, policies or practices, or regarding the general direction of Sunesis.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | SUNESIS PHARMACEUTICALS, INC. |
| | |
| Dated: June 19, 2008 | |
| | By: | /s/ ERIC H. BJERKHOLT | |
| | | Eric H. Bjerkholt |
| | | Senior Vice President, Corporate Development and Finance and Chief Financial Officer |
